CSL Plunges Most Ever on Impairments, Reduced Profit Target
BonTradeCSL Ltd. plunged the most on record after the Australian biotechnology company cut its full-year outlook and flagged about $5 billion in additional impairments, warning a turnaround will take longer than expected following a review by its interim chief executive.
